INTER-INDIVIDUAL VARIATIONS IN TACROLIMUS TREATED PATIENTS WITH RENAL TRANSPLANTS: CASE FOR PHARMACOGENTIC MONITORING

Authors

  • Vikas Dhikav Department of Neurology, Postgraduate Institute of Medical Education & Research, Dr. Ram Manohar Lohia Hospital, New Delhi, 110001, INDIA
  • Sandeep Guleria Department of Surgery, All India Institute of Medical Sciences, New Delhi, INDIA

Abstract

Tacrolimus is a widely used drug for renal transplant now a days. In India, it popularity has grown in recent times. One of the important feature of tacrolimus metabolism is that it has wide variation in pharmacokinetcics. Main reasons of pharmacokinetic variations are variations in intestinal and hepatic metabolism. As a result; there are wide intra and inter-patient variations. However, the incidence of these variations is not clearly known. Pharmacogentic monitoring of drugs with unpredictable pharmakinetics could be a new tool towards individualization of drug therapy. It has been known for sometime that inter-individual variations contribute to drug toxicity and inferior transplant outcomes. We were interested in studying the relationship between dose and concentration in Indian patients who underwent renal transplant and to know its implications.Keywords: tacrolimus, ultra-rapid metabolism 

Author Biography

Sandeep Guleria, Department of Surgery, All India Institute of Medical Sciences, New Delhi, INDIA

Department of Surgery, All India Institute of Medical Sciences, New Delhi, INDIA

References

Bowman LJ, Brennan DC. Expert Opin Pharmacother. 2008;9(4):635-43.

Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002 ;72(6):660-9.

Marquet P, Djebli N, Picard N. [Pharmacogenetics and immunosuppressor drugs: impact and clinical interest in transplantation] 1: Ann Pharm Fr. 2007;65(6):382-9.

Yu SF, Wu LH, Zheng SS. Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int. 2006;5(3):337-44.

Wavamunno MD, Chapman JR. Individualization of immunosuppression: concepts and rationale. Curr Opin Organ Transplant. 2008;13(6):604-8.

Vesell ES. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol. 2000 Sep;40(9):930-8.

Tung TH. Tacrolimus (FK506): Safety and Applications in Reconstructive Surgery. Hand (N Y). 2009 Apr 11. [Epub ahead of print]

Fukudo M. Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis. Yakugaku Zasshi. 2007 ;127(7):1081-9.

Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006 ;112(1):184-98. Epub 2006 Jun 8.

Hesselink DA, van Gelder T, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics. 2005 Jun;6(4):323-37.

Sommerer C, Giese T, Meuer S, Zeier M. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant. 2009 Jan;24(1):21-7. Epub 2008 Oct 8.

Downloads

Published

2017-01-15

How to Cite

Dhikav, V., & Guleria, S. (2017). INTER-INDIVIDUAL VARIATIONS IN TACROLIMUS TREATED PATIENTS WITH RENAL TRANSPLANTS: CASE FOR PHARMACOGENTIC MONITORING. Innoriginal: International Journal of Sciences. Retrieved from https://innoriginal.com/index.php/iijs/article/view/57